drugset / Trial / NCT02754362
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a phase II study to determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.
Timeline
- Start
- 2016-11
- Primary completion
- 2019-06
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | EGFRvIII peptide | Unknown | 100 ug | — |
| Subject | EphA2 peptide | Unknown | 100 ug | — |
| Subject | Her2/neu peptide | Unknown | 100 ug | — |
| Subject | IL13Ralpha peptide | Unknown | 100 ug | — |
| Subject | YKL-40 peptide | Unknown | 100 ug | — |
| Background | Hiltonol | Other / unclassified | — | — |
| Background | keyhole limpet hemocyanin | Vaccine | — | — |